Argenx Se (ARGX)

$471.32

+4.76

(+1.02%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $466.45
    $471.80
    $471.32
    downward going graph

    1.03%

    Downside

    Day's Volatility :1.13%

    Upside

    0.1%

    downward going graph
  • $327.73
    $550.76
    $471.32
    downward going graph

    30.47%

    Downside

    52 Weeks Volatility :40.49%

    Upside

    14.42%

    downward going graph

Returns

PeriodArgenx SeSector (Health Care)Index (Russel 2000)
3 Months
29.52%
5.9%
0.0%
6 Months
27.16%
5.5%
0.0%
1 Year
-11.72%
10.9%
0.0%
3 Years
48.98%
15.6%
-17.0%

Highlights

Market Capitalization
28.1B
Book Value
$69.22
Earnings Per Share (EPS)
-5.7
PEG Ratio
0.0
Wall Street Target Price
509.81
Profit Margin
-22.59%
Operating Margin TTM
-22.21%
Return On Assets TTM
-6.85%
Return On Equity TTM
-8.54%
Revenue TTM
1.5B
Revenue Per Share TTM
1.0
Quarterly Revenue Growth YOY
79.4%
Gross Profit TTM
-251.8M
EBITDA
-304.2M
Diluted Eps TTM
-5.7
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.82
EPS Estimate Next Year
4.37
EPS Estimate Current Quarter
-0.86
EPS Estimate Next Quarter
-0.82

Analyst Recommendation

Buy
    72%Buy
    24%Hold
    4%Sell
Based on 25 Wall street analysts offering stock ratings for Argenx Se(by analysts ranked 0 to 5 stars)
Based on 25 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
18
19
Hold
6
6
6
Sell
1
00
00

Analyst Forecast

What analysts predicted

Upside of 8.17%

Current $471.32
Target $509.81

Technicals Summary

Sell

Neutral

Buy

Argenx Se is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Argenx Se
Argenx Se
20.29%
27.16%
-11.72%
48.98%
215.2%
Moderna, Inc.
Moderna, Inc.
-9.73%
21.69%
-3.08%
-61.31%
759.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
2.19%
14.34%
48.43%
82.37%
258.01%
Novo Nordisk A/s
Novo Nordisk A/s
-7.8%
21.53%
62.25%
194.33%
441.74%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.55%
12.21%
36.13%
144.99%
180.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Argenx Se
Argenx Se
NA
NA
0.0
-2.82
-0.09
-0.07
NA
69.22
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.06
32.06
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.67
31.67
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Argenx Se
Argenx Se
Buy
$28.1B
215.2%
NA
-22.59%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
759.82%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$119.6B
258.01%
32.06
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
441.74%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
180.32%
31.67
39.46%

Insights on Argenx Se

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 407.43M → 401.00M (in $), with an average decrease of 1.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -99.31M → -61.59M (in $), with an average increase of 61.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 62.3% return, outperforming this stock by 74.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 194.3% return, outperforming this stock by 145.3%

Institutional Holdings

  • T. Rowe Price Associates, Inc.

    9.26%
  • FMR Inc

    5.50%
  • Artisan Partners Limited Partnership

    5.37%
  • HHG PLC

    3.73%
  • T. Rowe Price Investment Management,Inc.

    3.56%
  • Capital World Investors

    3.14%

Corporate Announcements

  • Argenx Se Earnings

    Argenx Se’s price-to-earnings ratio stands at None

    Read More

Company Information

Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

Organization
Argenx Se
Employees
1148
CEO
Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc.
Industry
Health Technology

FAQs